New therapies for early Alzheimer’s disease, monoclonal antibodies that remove amyloid-β plaques in the brain, are bringing hope to people whose lives have been affected by the disease.
Menu
Share this article COYA 302 is an investigational combination drug made up of a low dose interleukin 2 (IL-2) drug and a CTLA4 Ig fusion
Research explores the profound impact of climate change on neurological health, focusing on how rising temperatures, extreme weather, and air pollution exacerbate conditions like epilepsy,